Literature DB >> 25006392

A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?

Gerald Maarman1, Sandrine Lecour1, Ghazwan Butrous2, Friedrich Thienemann3, Karen Sliwa1.   

Abstract

Pulmonary hypertension (PH) is a disorder that develops as a result of remodeling of the pulmonary vasculature and is characterized by narrowing/obliteration of small pulmonary arteries, leading to increased mean pulmonary artery pressure and pulmonary vascular resistance. Subsequently, PH increases the right ventricular afterload, which leads to right ventricular hypertrophy and eventually right ventricular failure. The pathophysiology of PH is not fully elucidated, and current treatments have only a modest impact on patient survival and quality of life. Thus, there is an urgent need for improved treatments or a cure. The use of animal models has contributed extensively to the current understanding of PH pathophysiology and the investigation of experimental treatments. However, PH in current animal models may not fully represent current clinical observations. For example, PH in animal models appears to be curable with many therapeutic interventions, and the severity of PH in animal models is also believed to correlate poorly with that observed in humans. In this review, we discuss a variety of animal models in PH research, some of their contributions to the field, their shortcomings, and how these have been addressed. We highlight the fact that the constant development and evolution of animal models will help us to more closely model the severity and heterogeneity of PH observed in humans.

Entities:  

Keywords:  chronic hypoxia; monocrotaline; pulmonary arterial banding; right ventricular failure

Year:  2013        PMID: 25006392      PMCID: PMC4070827          DOI: 10.1086/674770

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  184 in total

1.  HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia.

Authors:  D M Stroka; T Burkhardt; I Desbaillets; R H Wenger; D A Neil; C Bauer; M Gassmann; D Candinas
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

2.  Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?

Authors:  N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

3.  The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally.

Authors:  Edwina Cahill; Simon C Rowan; Michelle Sands; Mark Banahan; Donal Ryan; Katherine Howell; Paul McLoughlin
Journal:  Exp Physiol       Date:  2012-02-24       Impact factor: 2.969

Review 4.  Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH.

Authors:  J Ryan; K Bloch; S L Archer
Journal:  Int J Clin Pract Suppl       Date:  2011-08

5.  Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat.

Authors:  Xiao-dong Xia; Zheng-jie Xu; Xiao-guang Hu; Cheng-yun Wu; Yuan-rong Dai; Lei Yang
Journal:  Cell Biochem Funct       Date:  2012-01-31       Impact factor: 3.685

6.  C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade.

Authors:  Brian Casserly; Jeffrey M Mazer; Alexander Vang; Elizabeth O Harrington; James R Klinger; Sharon Rounds; Gaurav Choudhary
Journal:  Life Sci       Date:  2011-07-27       Impact factor: 5.037

Review 7.  Reactive oxygen species and RhoA signaling in vascular smooth muscle: role in chronic hypoxia-induced pulmonary hypertension.

Authors:  Thomas C Resta; Brad R S Broughton; Nikki L Jernigan
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

8.  Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.

Authors:  Gaurav Choudhary; Frederick Troncales; Douglas Martin; Elizabeth O Harrington; James R Klinger
Journal:  J Heart Lung Transplant       Date:  2011-05-08       Impact factor: 10.247

9.  Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats.

Authors:  N S Hill; R R Warburton; L Pietras; J R Klinger
Journal:  J Appl Physiol (1985)       Date:  1997-10

10.  Smad signaling in the rat model of monocrotaline pulmonary hypertension.

Authors:  Margaret F Ramos; Michael W Lamé; Henry J Segall; Dennis W Wilson
Journal:  Toxicol Pathol       Date:  2008-03-26       Impact factor: 1.902

View more
  55 in total

1.  Shared gene expression patterns in mesenchymal progenitors derived from lung and epidermis in pulmonary arterial hypertension: identifying key pathways in pulmonary vascular disease.

Authors:  Christa Gaskill; Shennea Marriott; Sidd Pratap; Swapna Menon; Lora K Hedges; Joshua P Fessel; Jonathan A Kropski; DeWayne Ames; Lisa Wheeler; James E Loyd; Anna R Hemnes; Dennis R Roop; Dwight J Klemm; Eric D Austin; Susan M Majka
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

2.  Rebuttal from Krishna C. Penumatsa, Rod R. Warburton, Nicholas S. Hill and Barry L. Fanburg.

Authors:  Krishna C Penumatsa; Rod R Warburton; Nicholas S Hill; Barry L Fanburg
Journal:  J Physiol       Date:  2018-11-29       Impact factor: 5.182

3.  Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.

Authors:  Wei Zhuang; Guili Lian; Bangbang Huang; Apang Du; Genfa Xiao; Jin Gong; Changsheng Xu; Huajun Wang; Liangdi Xie
Journal:  Exp Biol Med (Maywood)       Date:  2018-08-12

Review 4.  Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature.

Authors:  Gerald J Maarman; Rainer Schulz; Karen Sliwa; Ralph Theo Schermuly; Sandrine Lecour
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

5.  TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction.

Authors:  Natasha M Rogers; Maryam Sharifi-Sanjani; Mingyi Yao; Kedar Ghimire; Raquel Bienes-Martinez; Stephanie M Mutchler; Heather E Knupp; Jeffrey Baust; Enrico M Novelli; Mark Ross; Claudette St Croix; Johannes C Kutten; Caitlin A Czajka; John C Sembrat; Mauricio Rojas; David Labrousse-Arias; Timothy N Bachman; Rebecca R Vanderpool; Brian S Zuckerbraun; Hunter C Champion; Ana L Mora; Adam C Straub; Richard A Bilonick; Maria J Calzada; Jeffrey S Isenberg
Journal:  Cardiovasc Res       Date:  2016-10-13       Impact factor: 10.787

6.  5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77.

Authors:  Ling-Yue Sun; Zong-Ye Cai; Jun Pu; Jian Li; Jie-Yan Shen; Cheng-de Yang; Ben He
Journal:  Inflammation       Date:  2017-06       Impact factor: 4.092

Review 7.  The emerging role of microRNAs in hypoxia-induced pulmonary hypertension.

Authors:  Vahid Mohsenin
Journal:  Sleep Breath       Date:  2016-05-07       Impact factor: 2.816

8.  Preventive aerobic training exerts a cardioprotective effect on rats treated with monocrotaline.

Authors:  Francis Lopes Pacagnelli; Ana Karênina Dias de Almeida Sabela; Katashi Okoshi; Thaoan Bruno Mariano; Dijon Henrique Salomé Campos; Robson Francisco Carvalho; Antônio Carlos Cicogna; Luiz Carlo Marques Vanderlei
Journal:  Int J Exp Pathol       Date:  2016-07-01       Impact factor: 1.925

9.  New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions.

Authors:  Thomas Mondritzki; Philip Boehme; Lena Schramm; Julia Vogel; Ilka Mathar; Peter Ellinghaus; Peter Kolkhof; Erwin Bischoff; Jörg Hüser; Wilfried Dinh; Peter Sandner; Hubert Truebel
Journal:  Eur J Appl Physiol       Date:  2017-11-20       Impact factor: 3.078

10.  Endothelial HIF-2α contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition.

Authors:  Haiyang Tang; Aleksandra Babicheva; Kimberly M McDermott; Yali Gu; Ramon J Ayon; Shanshan Song; Ziyi Wang; Akash Gupta; Tong Zhou; Xutong Sun; Swetaleena Dash; Zilu Wang; Angela Balistrieri; Qiuyu Zheng; Arlette G Cordery; Ankit A Desai; Franz Rischard; Zain Khalpey; Jian Wang; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-10-26       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.